EE200200185A - NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid - Google Patents

NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid

Info

Publication number
EE200200185A
EE200200185A EEP200200185A EEP200200185A EE200200185A EE 200200185 A EE200200185 A EE 200200185A EE P200200185 A EEP200200185 A EE P200200185A EE P200200185 A EEP200200185 A EE P200200185A EE 200200185 A EE200200185 A EE 200200185A
Authority
EE
Estonia
Prior art keywords
receptor antagonist
synergistic combinations
structural analog
gaba
gaba structural
Prior art date
Application number
EEP200200185A
Other languages
English (en)
Estonian (et)
Inventor
Hughes John
Singh Lakhbir
Original Assignee
Warner-Lambert Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company filed Critical Warner-Lambert Company
Publication of EE200200185A publication Critical patent/EE200200185A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Addiction (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EEP200200185A 1999-10-07 2000-10-05 NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid EE200200185A (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15827199P 1999-10-07 1999-10-07
PCT/EP2000/009858 WO2001024792A1 (en) 1999-10-07 2000-10-05 Synergistic combinations of an nk1 receptor antagonist and a gaba structural analog

Publications (1)

Publication Number Publication Date
EE200200185A true EE200200185A (et) 2003-04-15

Family

ID=22567369

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200185A EE200200185A (et) 1999-10-07 2000-10-05 NK1 retseptori antagonisti ja GABA struktuurse analoogi sünergistilised kombinatsioonid

Country Status (38)

Country Link
EP (2) EP1221950B1 (is)
JP (2) JP2003510356A (is)
KR (1) KR20020060192A (is)
CN (1) CN1387434A (is)
AP (1) AP2002002501A0 (is)
AR (1) AR029646A1 (is)
AT (1) ATE269072T1 (is)
AU (2) AU7663300A (is)
BG (1) BG106548A (is)
BR (1) BR0014598A (is)
CA (1) CA2385930A1 (is)
CO (1) CO5280195A1 (is)
CR (1) CR6614A (is)
CZ (1) CZ20021116A3 (is)
DE (1) DE60011650T2 (is)
DK (1) DK1221950T3 (is)
EA (1) EA004266B1 (is)
EE (1) EE200200185A (is)
ES (1) ES2220542T3 (is)
GT (1) GT200000166A (is)
HR (1) HRP20020286A2 (is)
HU (1) HUP0203466A3 (is)
IL (1) IL148965A0 (is)
IS (1) IS6318A (is)
MA (1) MA26826A1 (is)
MX (1) MXPA02003484A (is)
NO (1) NO20021625D0 (is)
NZ (1) NZ517949A (is)
OA (1) OA12063A (is)
PA (1) PA8504301A1 (is)
PE (1) PE20010708A1 (is)
PL (1) PL357498A1 (is)
PT (1) PT1221950E (is)
SK (1) SK4542002A3 (is)
TR (1) TR200200913T2 (is)
UY (1) UY26376A1 (is)
WO (2) WO2001024792A1 (is)
ZA (1) ZA200202675B (is)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0934061B3 (en) 1996-07-24 2015-01-21 Warner-Lambert Company LLC Isobutylgaba and its derivatives for the treatment of pain
US8048917B2 (en) 2005-04-06 2011-11-01 Xenoport, Inc. Prodrugs of GABA analogs, compositions and uses thereof
MXPA04011529A (es) * 2002-04-24 2005-08-15 Cypress Bioscience Inc Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension.
US20060039968A1 (en) * 2002-10-08 2006-02-23 Ramalingam Manikandan Gabapentin tablets and method for their preparation
US20060264509A1 (en) * 2003-03-21 2006-11-23 Fraser Matthew O Methods for treating pain using smooth muscle modulators and a2 subunit calcium channel modulators
WO2004084881A1 (en) * 2003-03-21 2004-10-07 Dynogen Pharmaceuticals, Inc. METHODS FOR TREATING FUNCTIONAL BOWEL DISORDERS USING α2δ SUBUNIT CALCIUM CHANNEL MODULATORS WITH SMOOTH MUSCLE MODULATORS
KR100742001B1 (ko) * 2003-03-21 2007-07-23 다이노젠 파마세우티컬스, 인코포레이티드 평활근 모듈레이터 및 알파2 델타 서브유닛 칼슘 채널모듈레이터를 이용한 하부 요로 질환의 치료 방법
EP1543831A1 (en) * 2003-12-18 2005-06-22 Pfizer GmbH Arzneimittelwerk Gödecke Pregabalin composition
DE102007019071A1 (de) * 2007-04-23 2008-10-30 Ratiopharm Gmbh Stabilisierte pharmazeutische Zusammensetzung enthaltend Pregabalin
KR101786818B1 (ko) 2010-07-30 2017-10-18 도레이 카부시키가이샤 신경장애성 동통의 치료제 또는 예방제
CN107050456B (zh) * 2010-09-28 2022-08-12 加利福尼亚大学董事会 治疗代谢综合征相关疾病的gaba激动剂和治疗或预防i型糖尿病的gaba组合
FI3946260T3 (fi) * 2019-03-26 2026-03-24 Orion Corp Pregabaliiniformulaatioita ja niiden käyttö
WO2022234110A1 (en) * 2021-05-07 2022-11-10 Plus Vitech, S.L. Gamma-aminobutyric acid derivatives for use in cancer therapy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression
US5792796A (en) * 1994-07-27 1998-08-11 Warner-Lambert Company Methods for treating anxiety and panic
US5510381A (en) * 1995-05-15 1996-04-23 Warner-Lambert Company Method of treatment of mania and bipolar disorder
AU726745B2 (en) * 1996-10-07 2000-11-16 Merck Sharp & Dohme Limited CNS-penetrant NK-1 receptor antagonists as antidepressant and/or an anti-anxiety agent
CA2273785A1 (en) * 1996-12-02 1998-06-11 Raymond Baker Use of nk-1 receptor antagonists for treating severe anxiety disorders

Also Published As

Publication number Publication date
BR0014598A (pt) 2002-06-11
PT1221950E (pt) 2004-08-31
PA8504301A1 (es) 2002-08-26
JP2003510356A (ja) 2003-03-18
HRP20020286A2 (en) 2003-08-31
ZA200202675B (en) 2003-04-15
EP1221950B1 (en) 2004-06-16
WO2001024791A1 (en) 2001-04-12
ATE269072T1 (de) 2004-07-15
AP2002002501A0 (en) 2002-06-30
BG106548A (en) 2002-12-29
UY26376A1 (es) 2000-12-29
IL148965A0 (en) 2002-11-10
WO2001024792A9 (en) 2002-09-06
AU7663300A (en) 2001-05-10
SK4542002A3 (en) 2003-09-11
TR200200913T2 (tr) 2002-09-23
KR20020060192A (ko) 2002-07-16
JP2003510355A (ja) 2003-03-18
CO5280195A1 (es) 2003-05-30
DK1221950T3 (da) 2004-09-20
PL357498A1 (en) 2004-07-26
OA12063A (en) 2006-05-03
NO20021625L (no) 2002-04-05
HUP0203466A3 (en) 2005-03-29
HUP0203466A2 (hu) 2003-02-28
NO20021625D0 (no) 2002-04-05
PE20010708A1 (es) 2001-07-27
GT200000166A (es) 2002-03-30
ES2220542T3 (es) 2004-12-16
AU1696201A (en) 2001-05-10
MXPA02003484A (es) 2004-09-10
CA2385930A1 (en) 2001-04-12
CN1387434A (zh) 2002-12-25
EP1233766A1 (en) 2002-08-28
IS6318A (is) 2002-03-21
EA004266B1 (ru) 2004-02-26
NZ517949A (en) 2003-08-29
EA200200303A1 (ru) 2002-08-29
CZ20021116A3 (cs) 2003-05-14
DE60011650D1 (de) 2004-07-22
MA26826A1 (fr) 2004-12-20
WO2001024792A1 (en) 2001-04-12
AR029646A1 (es) 2003-07-10
EP1221950A1 (en) 2002-07-17
DE60011650T2 (de) 2005-07-14
CR6614A (es) 2003-12-04

Similar Documents

Publication Publication Date Title
PT1204663E (pt) Novos compostos espiro com actividade antagonista do neuropeptido y
NO993616D0 (no) Anlegg- og kronesystem for bruk med dentalimplantater
EE200300145A (et) Asa- ja polüasanaftalenüülkarboksamiidid ja farmatseutiline kompositsioon
EE200300108A (et) Kondenseerunud heterotsüklilised suktsiinimiidiühendid ja nende analoogid kui tuuma hormooniretseptori funktsiooni modulaatorid
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
PT1165069E (pt) Composicao sinergistica antitumoral
EE05585B1 (et) Indasoolihendid ja farmatseutilised kompositsioonid proteiini kinaaside inhibeerimiseks ning nende kasutamine
FR2799954B1 (fr) Compostion de ciment dentaire verre-ionomere
PT1230230E (pt) Derivados de indeno-di-hidrotiazole sua preparacao e sua utilizacao como medicamentos anorexigenico
EE200200281A (et) Pikornaviirusevastased ühendid ja kompositsioonid, nende farmatseutilised kasutusalad ning ained nende sünteesiks
DE60011650D1 (de) Synergistische kombination von nk1-rezeptor antagonisten und gaba analogen
BR0014560B1 (pt) uso de uma composiÇço de tratamento de tecidos.
DK0923550T3 (da) Acylaminoalkylen-amid-derivater som NK1- og NK2-antagonister
EE200100631A (et) Amlodipiini ja atorvastatiini ühised eelravimid
IL154358A0 (en) Treatment of hiv-1 infection and inflammatory disease using cyclophilin receptor antagonists
BR9503015A (pt) Oligonucleotídeo composições terapêuticas e uso de uma composição
EE04095B1 (et) Ketoliidide ja nende farmatseutiliselt vastuvõetavate soolade kasutamine farmatseutiliste kompositsioonide valmistamiseks
ATE314846T1 (de) Synergistische wirkungen von amlodipin und dem hydroxylierten metabolit von atorvastatin
DE50010255D1 (de) Dübel
BR7700284U (pt) Componente modular de alvenaria para contrução civil
HUP9903183A3 (en) Use of olanzapine for the preparation of pharmaceutical compositions with analgetic activity
BR7701327U (pt) Escova dental com carga injetável
ITFI990215A0 (it) Uso della meftormina per la preparazione di composizioni farmaceutich e per l'inibizione dell'enzima dipeptidil peptidasi iv
ATE319448T1 (de) Therapeutische zusammensetzung von amlodipin und benazepril
FI960435A0 (fi) Lääkkeiden transdermaalisen antotapaan tarkoitettuLääkkeiden transdermaalisen antotapaan tarkoitettu koostumus koostumus